Latest:
Dr. El-Rayes on the Efficacy of Tidutamab in Advanced NETs
Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Beata Jagielska, MD, PhD
Latest:
Dr. Jagielska on Long-Term Survival With Lapatinib Plus Capecitabine in HER2+ Breast Cancer
Beata Jagielska, MD, PhD, internist, Centrum Medyczne Damiana Warsaw, discusses long-term survival with lapatinib (Tykerb) plus capecitabine in patients with HER2-positive breast cancer.
Becky Clark, MS, CGC
Latest:
CMS Should Broaden Coverage for Germline Mutation Testing
Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.
Ben Leach
Latest:
Immediate Impact Anticipated From Neoadjuvant Pertuzumab
The new indication for pertuzumab (Perjeta) as part of a three-drug neoadjuvant regimen for patients with HER2-positive metastatic breast cancer marks the first time the FDA has authorized a therapy based on pathologic complete response.
Benjamin A. Gartrell, MD
Latest:
Dr. Gartrell on Tolerability of SM-88 in Prostate Cancer
Benjamin A. Gartrell, MD, assistant professor of urology, Albert Einstein College of Medicine, medical oncologist, Montefiore Medical Center, discusses the tolerability of SM-88 in the treatment of patients with prostate cancer.
Benjamin A. Youngblood, PhD
Latest:
Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors
Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.
Benjamin D. Smith, MD
Latest:
Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer
Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.
Benjamin L. Ebert, MD, PhD
Latest:
Research Findings Point to Clinical Importance of Clonal Hematopoiesis
Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.
Benjamin L. Lampson, MD, PhD
Latest:
Dr. Lampson on Safety and Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab in CLL
Benjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, discusses preliminary safety and efficacy results from a phase II study of acalabrutinib (Calquence), venetoclax (Venclexta), and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL).